Related Blog Posts
Prostate Cancer - Vitamins Healing Or Preventing by Heinz Golz
23 hours ago ago from Submit articles | Post articles | Free articles | Article Directory at Articles-Heaven
Prostate Cancer - Vitamins Healing Or Preventing Article Directory Health and Fitness Cancer Articles Prostate Cancer - Vitamins Healing Or Preventing by Heinz Golz [ Publish Date: Tuesday, December 08, 2009] [ Viewed: 56] [ Comments: 0] [ Words: 486] Send To Friends - Report Article Prostate cancer is the most common cancer ...
Related contentEsophageal Cancer Treatment | Cancer Information
29 minutes ago ago from Cancer Information | Symptom, Prevention And Treatment
A new technique is showing promise in saving the lives of people with cancer of the esophagus. It's minimally invasive and the recovery time is quicker than ever. H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida is leading the way in the laparoscopic esophagectomy. This is one of the fastest rising cancers in the United States. 14000 Americans are diagnosed every year. Moffitt's Dr. Scott Kelley is one of the few surgeons ...
Related contentBreast Cancer Treatment: Hyperthermia with RT and CT | Cancer Information
29 minutes ago ago from Cancer Information | Symptom, Prevention And Treatment
This is two separate news stories about one breast cancer patient. One is during her hyperthermia treatment and one is afterwards. Hyperthermia therapy is a treatment used in battling cancer by heating tumors. The Heating is about as warm as a hot tub. Research has shown that heat can damage or kill cancer cells in some tumors while also making radiation and chemotherapy more effective. While it has been known for hundreds of years that ...
Related contentSome complementary mesothelioma therapies can be harmful
18 hours ago ago from Mesothelioma News
Dr. Kathleen Wesa of Memorial Sloan Kettering Cancer Center in New York and New Jersey presented research on complementary therapies used in conjunction with traditional forms of cancer treatment at the International Symposium on Malignant Mesothelioma . U.S. consumers spend an estimated $40 billion each year on complementary therapies and alternative treatments that are often unsupported by research. Cancer patients, including those with ...
Related contentBreast Cancer Awareness Month (part 4)
13 hours ago ago from Niche Tip
GE Global Research efforts to develop personalized treatment options for cancer patients.
Related contentRelated News
New drug is good news for cancer patients, but not for its maker's stock
18 hours ago ago from DailyFinance
New Jersey-based drug company Celgene ( CELG ) on Monday reported highly anticipated data for Revlimid, its multiple myeloma cancer pill. And it didn't disappoint : at the annual American Society of Hematology meeting, Celgene showed that Revlimid reduced the risk of progression by 50% among newly diagnosed patients who used the drug and chemotherapy, followed by maintenance therapy, compared with those who only used chemotherapy. Patients ...
Related contentAbraxis Provides Overview of ABRAXANE® Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
1 day ago ago from Good News Now
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE ® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13. Clinical results from ...
Related contentGenzyme’s Mozobil Shows Promise in Chemosensitization
23 hours ago ago from FanHouse
Genzyme Corporation (Nasdaq: GENZ) announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil® (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow. The investigational trial, partially supported by Genzyme, was the subject of an oral presentation at the 2009 annual meeting of the American Society of Hematology in New Orleans, LA. ...
Related contentLong-Term BEXXAR(R) Data Demonstrate Overall Survival
23 hours ago ago from Good News Now
Long-term Results in both First-line and Refractory Settings Seen in Patients with Non-Hodgkin's Lymphoma PHILADELPHIA, Dec. 8 /PRNewswire/ -- GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR ® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes ...
Related content
